Home / Transcripts / Ultragenyx Pharmaceutical Inc. (RARE) · November 3, 2026

Ultragenyx Pharmaceutical Inc. (RARE) Earnings Call Transcript

November 3, 2026

NASDAQ US Health Care Biotechnology earnings 60 min

Earnings Call Speaker Segments

Joshua Higa executive
#1

Thank you. A press release is out with our financial results, and you'll find it posted on our site at ultragenyx.com. With me today are Emil Kakkis, our Chief Executive Officer and President, Howard Horn, our Chief Financial Officer, Erik Harris, our Chief Commercial Officer, and Eric Crombez, our Chief Medical Officer. I want to remind everybody that on today's call we'll be making forward-looking statements. Those statements carry certain risks and uncertainties, and our actual results could differ materially. Please see the risk factors discussed in our latest SEC filings. I'll now hand the call over to Emil.

Emil Kakkis executive
#2

Thanks, Josh, and good afternoon to all of you. Ultragenyx had a momentous third quarter in a number of respects; during August and September, the FDA gave the green light to GENGLYCOS for glycogen storage disease type Ia and to FAYUVI for Sanfilippo syndrome type A. Those clearances reflect years of effort from our teams and the original scientists, along with the families, patients, and investigators who participated in the trials. We also encountered the disappointing results from the GTX-102 phase III trial that caught us off guard, even though phase II data had been compelling, and that has now required substantial cutbacks throughout the organization. Through these measures, our cost base will align with our revenue. That leaves us well-positioned to keep commercializing our six products for patients with rare diseases and to invest thoughtfully in our development programs, while also turning profitable next year. Although the clinical trial failure on an important program that might have generated enormous value has been difficult for us, we ought to acknowledge everything this company has achieved in its 12 years as a public company. Today we hold six product approvals for first-ever treatment indications spanning multiple treatment modalities, and we are generating worldwide revenue growth of roughly 20% annually across multiple years, on the way to $1 billion+ in revenue and profitability. Even as we recognize a setback today, when I founded the company with $2 million and a secretary, it would have astonished and inspired me to learn that we had grown into a highly respected and admired team of a thousand professionals treating thousands of patients with rare and ultra-rare diseases across the globe. There remains more to do, and today we will lay out the steps we are taking to bring the company into its next stage as a profitable business driving commercialization and development of first-ever treatments for rare diseases. First, I'll turn to the launch of our two new gene therapy products. Each of these products offers meaningful and transformative options for these rare disease patients and their families. For those living with glycogen storage disease type Ia, disease management requires consuming cornstarch every few hours, day and night, since a missed dose may cause potentially life-threatening hypoglycemia. GENGLYCOS is the first FDA-approved treatment option for such patients and could reduce their reliance on cornstarch, lightening the constant care burden that shapes their lives. The second approval granted during the quarter was for Sanfilippo syndrome type A, a fatal neurologic disease whose onset comes in early childhood. At birth, these children look normal, hitting developmental milestones just as their peers do. That holds through the first months, but then halts, and over the following few years, as the children progressively lose cognition, language, and motor function until they become unresponsive and bedridden for years prior to death. Up to now, families affected by Sanfilippo syndrome type A have had no approved therapy. FAYUVI can now be given to these families as one IV infusion administered on an outpatient basis, which offers them a way to meaningfully alter what lies ahead for their children; that is the promise gene therapy was meant to deliver. These approvals arrive at a moment when our clinical study was unable to establish efficacy for GTX-102 in Angelman syndrome. Even though some patients in phase II experienced transformative changes—something that forges such a powerful connection between us and the community—this outcome forced us to halt the clinical program. It likewise called for a thorough examination of every expense and priority we have, aimed at bringing our operating costs down so they align with revenue, letting us reach meaningful profitability both now and later, while still expanding the business. Cutting costs and ending a program inevitably involve steps that substantially shrink our workforce, and we feel deep gratitude for what those affected have given and are dedicated to supplying support and resources to them throughout this transition. As this process unfolded, we assessed UX701, our gene therapy for Wilson disease, and determined it fell short of the criteria needed to move into phase III. Because expenses must come down further, we have also decided to end the UX701 program in Wilson disease instead of attempting to pursue improvements. The dose-finding data, including results from cohort four, revealed clinical activity in certain patients, yet we did not see a majority of patients attain a sufficient biochemical response and stop standard of care therapy. Across all cohorts dosed, UX701 showed a favorable safety profile. I genuinely believe some patients derived meaningful benefits, among them individuals who came off their chelators and zinc therapy after receiving UX701. I believe as well that gene therapy is a rational way to treat Wilson disease better than it is treated today. Regrettably, we cannot keep investing to optimize the product for Wilson disease. We are collaborating with clinical sites and patient advocacy groups to assist study participants and the wider Wilson community through this transition. We plan to present data from the completed study at an upcoming medical or scientific congress so that our learnings reach the broader community; we thank every patient and investigator for what they contributed to the program; these were not easy choices, but they put us in position to focus on launching GENGLYCOS and FAYUVI well, to keep growing our base of commercial products, and to achieve profitability in 2027 and beyond. Turning into a self-sustaining company will underpin our ambition to lead the future of rare disease medicine. I will now hand the call to Chief Financial Officer Howard Horn, who will walk through the details of our expense reductions and our profitability.

Howard Horn executive
#3

Thank you, Emil, and good afternoon, everyone. You can find the details of our third quarter financials in our press release, and during Q&A I would be glad to take any questions about them. My remarks today will center on guidance for 2026 and 2027, including further detail and rationale regarding the expense reductions Emil just mentioned, along with what we expect for profitability. Beginning with 2026 guidance, we are reaffirming our revenue guidance for 2026, specifically that total 2026 revenue is expected to be $730 million-$760 million, which, as a reminder, excludes revenue from the launches of FAYUVI and GENGLYCOS, CRYSVITA 2026 revenue of $500 million-$520 million, and DOJOLVI 2026 revenue of $100 million-$110 million. We're also restating that we expect combined R&D plus SG&A expenses in 2026 to be flat to down low single digits compared with 2025. That figure reflects all of our cost-cutting actions, along with $30 million of severance and other non-recurring restructuring charges incurred in the first half of the year, and roughly $25 million of severance and other non-recurring restructuring charges anticipated to hit the fourth quarter. Turning to 2027 guidance: as we've done before, we plan to share full-year 2027 revenue guidance early in the new year. Looking at 2027, we anticipate R&D costs will come in under $350 million — a drop of over 50% compared with 2025 levels — and most of that 2027 R&D spending should go toward supporting our commercial products. For 2027 SG&A, we expect figures below $375 million, which would be as much as a 7% rise over 2025 levels; these R&D and SG&A projections represent considerable cuts in spending relative to what we previously guided. To hit these goals, we've already begun significant reductions in headcount and expenses. The steps we're taking include cutting roughly 20% of our positions, which brings us to a workforce of about 1,000 people. We'll move quickly to finish winding down every active study and the associated costs for GTX-102 in Angelman syndrome, discontinue UX701 for Wilson disease, and lower costs throughout the company—shrink our real estate footprint and resize G&A spending to match our new shape. In 2027, spending will concentrate on our commercial activities and a leaner, more focused R&D presence: finishing the phase III trial of DTX301 for OTC deficiency, settling on the next steps for UX143 in osteogenesis imperfecta, and funding early-stage programs at a disciplined level so they can advance toward future INDs. We're also restating today that we expect to reach GAAP net income profitability for the full year in 2027, and we anticipate generating positive cash flow from operating activities that year. The elements behind our capacity to hit profitability in 2027 match what I described on the August call: ongoing revenue growth from the four products we already have, along with contributions from our new gene therapy launches, plus disciplined expense management and capital allocation, as we just covered. In addition, during October we bolstered our balance sheet using non-dilutive capital by selling our two PRVs. The first transaction closed last week, and we expect the second to be finalized before the end of the month. Once you account for what we pay licensors and the associated fees, the net amount lands at about $350 million, and that figure will be recorded under other income in our 2026 financials. The profitability we expect in 2027 is driven by the core business and does not factor in any PRV-related income. The key point is that we already have on hand the cash needed to become profitable, so no additional fundraising will be required. Getting to profitability and staying there has been a central goal for the company, and we are thankful to now be in a position to make good on it. Lastly, to close, workforce reductions rank among the hardest aspects of running a business, and I want to repeat Emil's earlier words of thanks to our departing colleagues for what they contributed to Ultragenyx; with that, I'll hand the call over to our Chief Commercial Officer, Erik Harris, who will share more detail on how our current products are performing and on our two launches.

Erik Harris executive
#4

Thanks, and good afternoon everyone. The commercial side of our business has had a truly exciting few months: GENGLYCOS got the green light in August and FAYUVI in September, so our fifth and sixth approved medicines — also our first two gene therapies — are now getting to patients. Our teams spent years preparing for this moment, and I've been struck by how seamlessly they moved from approval into launch, kicking off the effort to reach the patients and families who've been waiting for these treatments. I will start with how the gene therapy launches are progressing, then move on to how our established products are performing; here in the U.S., the field team running the GENGLYCOS and FAYUVI launches is the very same group that has spent years supporting DOJOLVI and MEPSEVII. The strong relationships they hold and their experience calling on medical geneticists at the centers represent a major advantage as these launches scale up. Like other gene therapies, GENGLYCOS and FAYUVI are given at qualified treatment centers, or QTCs. The majority of those QTCs will administer both of the gene therapies. At the close of October, 35 QTCs were active, and we remain on track to surpass our goal of 40 QTCs by year-end. That network matters enormously for meeting the demand we anticipate for both products. Within just a few short weeks of these approvals, our team has already recorded meaningful demand for GENGLYCOS as well as FAYUVI, holding a significant number of enrollment forms, which confirms the high unmet need Emil mentioned. Feedback so far from KOLs has been highly favorable, with real enthusiasm from physicians who have been waiting for an approved treatment option to offer their patients. As tends to happen with newly approved FDA treatments, coverage decisions in the early launch period will mostly be handled on an individual patient basis, and both timing and requirements will differ from payer to payer. We expect broad payer coverage, though individual approvals could take extra time early in the launch. Our UltraCare Gene Therapy Guide team has already assisted the first patients and families in navigating coverage, and a number of them are now scheduled for infusions with approved reimbursed therapy; we look forward to sharing further updates on QTC activation, payer coverage, and most importantly, patients treated, on upcoming calls. Beyond America, the need that remains unmet is equally significant, and alongside the U.S. launch we're observing robust interest in gaining access to FAYUVI while we seek formal approvals, starting with the EMA and MHRA; as for GENGLYCOS, interest is similarly on the rise and we are pursuing formal approvals beyond the U.S. Now I'll turn to the established products, starting with CRYSVITA, which through the first three quarters of this year keeps delivering consistent growth compared with the equivalent period in 2025. As a reminder, Kyowa Kirin, our partner, handles commercialization of this important product across the U.S., Canada, and Europe, whereas our own teams commercialize it in Latin America and Türkiye. Between them, thousands of pediatric and adult patients have benefited from CRYSVITA. In Latin America, CRYSVITA continues to see robust underlying demand, powered by Brazil, Mexico, Argentina, and Colombia. Roughly 60 new patients started commercial therapy during the quarter, and over 1,050 patients in the region are now on commercial therapy. As we've noted on earlier calls, ordering patterns will likely produce some variability from quarter to quarter, yet underlying demand stays strong and keeps growing at a steady pace. In Türkiye, named patient demand remains solid, with patients accessing CRYSVITA every month. Based on what we've seen with case-by-case reimbursement in other nations, adoption tends to be slower initially, though demand continues to rise as healthcare professionals and patients see the advantages of this transformative treatment. Turning to DOJOLVI, we're seeing consistent expansion; close to 700 patients in North America are receiving reimbursed therapy. In 14 EMEA countries, roughly 315 patients are being treated through named patient or early access programs. In the U.K., DOJOLVI obtained conditional marketing authorization last week covering the full LC-FAOD indication, and my team is keen to begin working with physicians and patients there. The DOJOLVI launch in Japan has performed well, exceeding our expectations. We anticipate that worldwide demand for DOJOLVI will continue rising at a steady pace, driven by patients and physicians building firsthand familiarity with this important therapy and by the completion of further regulatory filings. So far this year, EVKEEZA has expanded by roughly 50% relative to the corresponding stretch of 2025, making it the standout growth driver during the third quarter. Across the markets outside the U.S. where we are responsible for commercialization, upwards of 500 patients in over 20 countries are now on EVKEEZA, while our teams keep making progress on reimbursement market by market, backing early access, and switching suitable patients over to reimbursed therapy. Across numerous markets, our share position outpaces competing options, and our teams continue to find and serve a greater portion of the widespread patient populations in the various regions. As we release additional demand, we anticipate that robust expansion will persist. To wrap up, we have ranked among the most efficient commercial operations in rare disease. Backed by a dedicated, seasoned staff and suitable collaborators, we deliver our therapies to patients in numerous nations, using our established footprint to introduce every new product and supply vital treatments to rare disease patients around the world. Bringing GENGLYCOS and FAYUVI on board gives us a lineup of six products, and as those launches layer onto our existing portfolio, we're on a path toward more than $1 billion in revenue. The chance to help steer profitability and future expansion at Ultragenyx has my team energized — and, even more importantly, to keep delivering life-saving treatments to people living with rare diseases. On that note, I'll hand things back to Emil for a few closing words.

Emil Kakkis executive
#5

Thank you, Erik. This past quarter brought a whole spectrum of feelings — along with the optimism and promise surrounding the approval of two treatments that are the first of their kind, gene therapies actually, and also the letdown we shared with families of patients dealing with Angelman syndrome and Wilson disease. We undertook the painful task of resizing every part of our organization so that we can operate as a self-sustaining company from here on. To those staff members who helped build our success and are now departing, we send our warmest wishes — carry our culture and that compassionate, determined spirit of advocating for rare disease families to wherever in the world you work. Your abilities and expertise will keep contributing to the mission we embarked on at Ultragenyx. The adjustments being put in place today position us for the coming chapter as a profitable enterprise that controls its own destiny. The flexibility these financial steps create will let us keep leading the future of rare disease, delivering innovative and life-changing therapies to patients who are waiting with great urgency. So with that, let's turn to your questions. Operator, please give the Q&A instructions.

Maury Raycroft analyst
#6

Hello, and thank you for fielding my question. I'd like to ask about next year's expenses, specifically regarding the guidance that R&D will come in under $350 million. You said most of that R&D spending would go toward supporting commercial products. Could you give us more detail on what those costs or obligations actually are, and are there further levers available to cut R&D even more? I'm curious whether any allocation within it is set aside for setrusumab development.

Emil Kakkis executive
#7

Certainly. Let me address a few points, and I may let Howard go into greater depth. The setrusumab spend is already included in that figure. The bulk of these expenses stems from the disease monitoring program, regulatory filings, and other items supporting filing approvals. I'll have Howard speak briefly about what falls within the $350 million, to the degree we can share that at this stage.

Howard Horn executive
#8

Yeah. Maury, appreciate the question. Yeah, so the guidance we have is under $350 million, and again, that represents a reduction of more than 50% compared with our 2025 R&D levels, and it's more than the 38% guidance that I believe we provided the last time we cited it. The strategy we laid out today is that we're concentrating on commercial execution and on a smaller, tighter R&D footprint. So, I think you'd expect that most of the R&D spend would be directed toward that commercial footprint, and that's what we quoted today, and how we intend to address it next year.

Maury Raycroft analyst
#9

Understood. Fine. Thanks for letting me ask my questions.

Kristen Kluska analyst
#10

Hi, everybody. I appreciate your taking my question tonight. Mine was also about setrusumab. I realize you can't yet share what the next steps will be, but maybe, just based on the recent data you've observed, it's evident that there is activity. Should we be thinking at this point that another trial is more likely? Is filing still a possibility here? If another trial were run, could you take us through some of the ways you're weighing how to reduce any risk for that trial, again, given that we know there is activity? Thank you.

Emil Kakkis executive
#11

Thanks, Kristen. On the data we presented at ASBMR, the piece I'd highlight as most salient was that in patients who had more than three fractures at baseline, we demonstrated a clinically meaningful reduction in fractures in that population — in both ORBIT and COSMIC. That tells us that among patients at higher risk of fractures, there's an important benefit from the increase in bone mineral density that you observe; whether we need to run another trial is something we really can't say at this point. We're currently looking at the pathway with the FDA and working through those discussions on what we would do. Here's what I believe we can say: this drug clearly has activity, and patients are showing a strong desire to remain on it. Our sense is that, given the profound and substantial biomarker data on BMD, along with supportive findings in areas such as pain and physical functioning, plus the fracture reduction seen in those with high fracture rates, we believe there is a valuable product here that we are working to pursue. We can't really characterize it at this stage because we're in the midst of negotiating with FDA over what that might mean, so I don't want to set any expectations right now. But we do believe there's a product in there. One thing we still need to settle is the timeline, along with the volume of data that would be needed. Still, it's a genuine product for OI, which we find encouraging, and now we have to determine the strongest path for advancing it.

Kristen Kluska analyst
#12

Thank you.

Joon Lee analyst
#13

Hello. Thanks for asking our question. That post-hoc OI analysis is genuinely interesting. I'd appreciate it if you could go into more detail on why the fracture data appears stronger against an IV bisphosphonate than against placebo. And to build on the earlier question, in your prospective study, might that serve as a confirmatory trial, with the expectation that approval could come on the basis of existing data? Thank you.

Emil Kakkis executive
#14

Yes. What you're alluding to is a study we ran in younger patients aged two to seven years, who were more severe and in fact had a higher rate of fracture. So in that population, we saw more fractures than we had, and an even greater fracture count in the control group, and post-hoc we could demonstrate a larger reduction that was statistically significant. So I think the main driver is that these are younger patients, they respond more consistently, and they started out with a higher fracture frequency; so there is simply more to detect. I do believe the fracture benefit showed up in both groups, and it's just that the higher-fracture subgroup among the COSMIC younger patients was able to demonstrate it more readily, even though the patient numbers, by the way, were smaller in the COSMIC subset; so with that said, I think there's potential for crossover data, but at this point I wouldn't want to tell you how that will be resolved. We have to work things through the FDA. They are working alongside us, and we appreciate their efforts in thinking this through, but we don't yet have an exact answer on how to use the combination data and get this product approved at this point.

Joon Lee analyst
#15

Thanks.

Jane Han analyst
#16

Hello. This is Jane, covering for Yaron. I want to explore setrusumab a little further. So my understanding is that you don't yet have firm plans or a route for whether another study will be required, but speaking hypothetically, if a second confirmatory trial were run for possible approval, do you believe it could be made smaller and shorter by enriching for frequent fractures? And as you consider future plans, what level of cost and what timeline would be acceptable given your reduced R&D budget? And then, when could we expect greater clarity on the decisions you'll move forward with? Many thanks.

Emil Kakkis executive
#17

Right. To start with the first part: any investments, as you can imagine, are made within a profitability framework. That's built into our plan for next year and beyond, and we'd be working inside those limits. At this point we think that's quite achievable. If a trial were needed, we'd definitely want to enrich for patients with more fractures, since that simply gives us greater signal to detect a change in fractures, and I think that would be a natural step. We'd also consider which age range to include, given that younger patients experience more fractures and show a higher response rate. We believe the medication likely works across every age group, though we'd want to identify the most sensible route—one targeting the greatest unmet need, and so on—that could lead to approval. Once we're nearer to that point, we'll share additional details, but there are factors to consider regarding what a trial would involve and how to enrich for the optimal population that would show the benefit. Regardless of our approach, those expenses are already factored into our assumption that we are profitable, and we will operate within those limits.

Jane Han analyst
#18

Great, thank you very much.

Joohwan Kim analyst
#19

Hello, Joohwan Kim here, filling in for Yigal. Appreciate you taking our questions; regarding FAYUVI, I just wanted to ask whether preserved neurodevelopmental function is being understood the same way by physicians and payers, or whether you're noticing any differences in eligibility determinations between centers or particularly between plans?

Emil Kakkis executive
#20

At this point we haven't encountered any problem. Plans are still being worked out. Erik may be able to give a bit more detail. Our reading of preserved neurodevelopmental function was that these are not non-responsive, bedridden patients. That describes a patient who has lost all neuro function. It does not mean their function is normal, correct? That reflects what we discussed with the agency, and we consider it a relatively broad label. Erik, are there any details from the policies that have been published, or anything you can share right now, about how much of an issue there is with neurocognitive function?

Erik Harris executive
#21

The conversations have been constructive and heartening, and consistent with what we anticipated, and the first set of policies has aligned with the label.

Emil Kakkis executive
#22

We have not seen restrictions in terms of-.

Erik Harris executive
#23

There are no limitations.

Emil Kakkis executive
#24

Right. That's great. So at this point, that's what you'd say.

Joohwan Kim analyst
#25

Understood. That's quite useful. I just have one brief question regarding setrusumab. I'm simply curious whether we should view the forthcoming decision mainly as a go or no-go call on yet another prospective study, or whether you're likewise weighing intermediate steps or studies that might boost confidence prior to committing to a full trial.

Emil Kakkis executive
#26

Well, I'd prefer not to frame it as go, no-go. There are, I think, many complexities involved. It's more a matter of what the best path forward is for advancing a drug that we believe has shown a meaningful effect on the bones of these OI patients, and how do we reach the clinic? So, I wouldn't see it exactly as go, no-go. It's somewhat more about what's the best and quickest route to bring the product through to patients.

Joohwan Kim analyst
#27

Got it. Thanks a lot.

Joshua Higa executive
#28

Ellie, we’re unable to hear you. Your line may be muted. Let me give you a moment to answer.

Jasmine Fels analyst
#29

Hello there. Is my voice coming through at this point?

Joshua Higa executive
#30

Yes, we can hear you perfectly. Please continue.

Jasmine Fels analyst
#31

Okay, great. Thank you. Jasmine here, filling in for Ellie. Appreciate you taking our question. I just wanted to ask if you could comment on what launch cadence you expect for both GENGLYCOS and FAYUVI. Should we anticipate a possible bolus for either one from pent-up demand, and how does that pace look for each in the first few quarters? Have any patients been treated with either so far? Thank you.

Emil Kakkis executive
#32

Yeah. I think let's discuss FAYUVI first, or start there. With FAYUVI, where kids are losing their brain every month, and families have been waiting and waiting for this treatment, there's definitely a bigger urgent push to get on drug right away. We'd expect some level of a surge at first, but what we think will happen is we'll begin adding more territories with the product, which will keep that going. While you're thinking of just the U.S., you should really think of this as global; we already have a lot of international requests for treatment as well. I think that will probably end up spreading out the drug's overall utilization, even though I think there will be some degree of a bolus. For GENGLYCOS, we expect it to develop a bit more methodically, not as urgently. The patients do have a treatment, it's just a question of crossing over to something that would make their lives better and perhaps provide less risk that they can have a crash and burn event. I forgot what the last-.

Joshua Higa executive
#33

What about the GENGLYCOS launch trajectory?

Emil Kakkis executive
#34

That is the very one I just covered.

Joshua Higa executive
#35

Have you treated patients yet?

Emil Kakkis executive
#36

Oh, yes, treated patients. Well, the process of treating patients has begun for us. We have multiple ones set up and so forth; we're not going to give any great detail exactly, but we're encouraged that things are getting lined up and going, so we're pretty happy about how it started.

Jasmine Fels analyst
#37

All right, that’s useful. Thanks.

Tazeen Ahmad analyst
#38

Hello, and thanks for the question. I’d like to ask one more about Sanfilippo. In your view, how will the competitive landscape change? Another company might launch a product of its own, possibly as soon as the end of next year. From what you’ve analyzed about the market opportunity, how many patients do you believe you could switch to your therapy, say, during the next 12 months? I’m just looking for a general sense. If another entrant does arrive, what would you describe as your product’s advantages compared with what they claim? Thank you.

Emil Kakkis executive
#39

Yes, thank you. I believe there are at least a couple of competing projects. One is enzyme replacement, the Denali product, and there is also another one, a lentivirus gene therapy. I think our product clearly stands out because it is a single IV infusion, and if you have ever had a small child and you have to take them for many infusions or put them through something like a bone marrow transplant, going to the hospital for one infusion and then returning home is simply a far lower bar and, in our view, a far lower risk. We see the kind of long-term data that none of the other programs have. Specifically, we have eight years of durable data, and we believe we have an excellent safety profile. So at present, we feel we are in the strongest position and that a single infusion will be best; we always examine the degree of efficacy, other matters people may question, and we keep looking at ways to further improve our product. But at this time, we feel that what we offer is probably the best choice for most families, especially if you have small children who are very young. I have not really discussed what we think the number of patients we will treat will be; it is really not the right moment for that. We will give an update early in January on how we are doing in terms of how many start forms and so forth. But we believe we are positioned to do extremely well with Vyondys. I think the simplicity of treatment and the reduction in medical interventions required will be the kinds of things families appreciate. Thank you, Tazeen.

Duke Tells analyst
#40

Hello, this is Duke Tells calling on behalf of Anupam Rama at JPMorgan. Thanks for fielding our question. You mentioned a little about what you're observing in the Wilson disease program, but could you take us through the reasoning behind deciding to discontinue it, please?

Emil Kakkis executive
#41

Sure. We had established the bar that for us to put money into a phase III program, we needed to see the majority of patients reach the biochemical effect and standard care withdrawal that gave us confidence their body had been sufficiently altered when it comes to copper metabolism to warrant a gene therapy. Although we did see some patients who were able to achieve that, it was not the majority. At this stage, with our need to keep expenses in check, it didn't seem that devoting a large sum of money to chasing this down would be the best moment for it. I think gene therapy is a sound strategy for Wilson. There may come a time when we return to it, but right now, we need to get ourselves into a more financially disciplined place, keep our expenses managed, and put ourselves in position to better control our future. While I believe Wilson is a good indication, I think at present there is still more work to be done before a gene therapy would be ready to do what we want to see, which is a truly complete change in copper metabolism that would give these patients a real future—a healthier future than what they have today.

Duke Tells analyst
#42

Great. Thanks a lot.

Maxwell Skor analyst
#43

Great. Thanks very much for asking. Directionally, over the longer term, can you give us a sense of where R&D spending is headed? And then, if I may, one quick follow-up. Regarding Angelman, could you share anything more about what caused the miss? Thank you.

Emil Kakkis executive
#44

Yeah. Directionally, on R&D, look, our pipeline was very full. Four or five phase III programs were running at the same time, which is a very large set. At present, we have one program with two phase III programs plus some early-stage work, and there are certain other potential INDs we would file, things we've been holding back on. The approach we intend to take is operating with a tighter, more concentrated scope while staying within profitable boundaries, and maintaining roughly five programs each year—which I believe is achievable on a sustainable basis for a company that is profitable. We will have the ability to introduce new items at the clinic; we'll be aiming higher, though we'll pursue that while keeping spending in check and without compromising our pledge on profitability. Turning to Angelman, we'll be sharing data shortly to talk through it, but the short version is that variability inside the control arm was simply too large for us to detect or differentiate their change, and that showed up across several endpoints rather than one specific endpoint; in our view, several factors deserve consideration. Looking at our phase II patients over a three-to-five-year span, we believe some of them do experience transformative benefit, yet across the full breadth of patients in a randomized trial that runs only one year in length, we are not seeing a distinctive separation on multiple endpoints. So our sense is that more work remains to be done. We think Angelman is a solid target and the approach itself is sound. What we accomplished simply fell short of getting us to the point we need to reach. Right now, many options and strategies for Angelman are in development, and we expect the community will keep working through this. That said, at this stage the endpoints vary so widely that clearly demonstrating an effect just isn't possible. Considering what the program costs and how much we need to bring expenses into line, we concluded that the stronger approach at present is to reduce our R&D footprint, concentrate on the ones already working, and place ourselves in a position to steer our future with greater precision.

Maxwell Skor analyst
#45

Thanks a lot.

Lydia Erdman analyst
#46

Hello, and good evening. Lydia here, filling in for Salveen. We really appreciate you taking our question. Perhaps regarding the two gene therapy launches, could you share which metrics you intend to give the Street, and how big a part these launches should play on the route to profitability next year? Many thanks.

Emil Kakkis executive
#47

Let me begin with the sort of items we would typically offer. Until we have several quarters behind us, guidance isn't something we'll give, so revenue guidance we won't provide; what we will provide is what we refer to as the early metrics, and those will be — we'll give you the revenue we bring in from this year, definitely, when we speak in early January. Our aim will be to discuss QTCs operating and start forms, and those would be the main cause. Down the road, we'll definitely begin including revenue once we have revenue. Naturally, we'll also cover payer coverage, which gets published, so much of that you'll see for yourselves. Those would be the items. Payer coverage, in terms of its character, will certainly be part of what we do. That would be, I suppose, the chief things we're going to set out. Oh, yes. Howard, of course. Please go ahead.

Howard Horn executive
#48

The second part of your question, I think, was around contribution to profitability.

Emil Kakkis executive
#49

Okay.

Howard Horn executive
#50

What I said before is that our core business is solid and expanding, and that, together with what these 2 launches add, will push revenue to the level that takes us into profit next year. We intend to give more detail on that early in 2027, so watch for it.

Lydia Erdman analyst
#51

Many thanks.

Jack Allen analyst
#52

Good. Appreciate you taking my questions. My question really focuses on CRYSVITA. You've demonstrated a strong, impressive capacity to keep growing this product year over year, and I wanted to ask what your present expectations are regarding the LOE timing for it. As I understand it, composition of matter in the U.S. runs to 2032, and there's some extra padding around the dosing paradigm. I'm just trying to figure out when biosimilars might potentially start encroaching on the CRYSVITA franchise.

Emil Kakkis executive
#53

Absolutely. Thank you; we're clearly very mindful of this, and our partner, Kyowa Kirin, and I have discussed it, and they've been doing work, as have we, on next-gen versions of CRYSVITA. So those efforts are underway, and we'd expect to have an improved version. What I'd tell you is that CRYSVITA itself is essentially a next-gen product already. It's fully bioavailable subcutaneously; it has no anti-drug antibody or hypersensitivity issues, and so it's been used chronically and very effectively. So it's a particularly good product. Developing the next-gen version that must improve on those characteristics, which could involve dosing less frequently or possible potency improvements; we're mindful of that, and we're doing the work to get ready for it. I'd note for you that in many of the areas where we operate, there really aren't any. Seldom, shall we say, do follow-on biologics appear. The key question would be what happens in the U.S. In the biologic areas, I wouldn't view LOE as a precipitous drop-off, at least in our opinion. But we do expect to have next-gen versions that we bring into play when the time arrives. With the improvement in the regulatory environment, we think it's actually fairly. You can be fairly prompt in assembling a development program that can verify, because phosphate control now is, in fact, a reasonable surrogate per the FDA's interpretation; so that places us in a better position to set up for the next stage. So, an important product; we'll keep supporting it globally, and we'll handle LOE effectively, I believe.

Jack Allen analyst
#54

Great, I appreciate the additional detail.

Joshua Higa executive
#55

Operator, let’s go ahead to the following question. Operator, we aren’t able to hear you, though Luca, if you’re able to hear us, I can see that you are in the queue. Kindly proceed.

Analyst analyst
#56

Appreciate you fitting in this question. Maybe I'll pivot to OTC deficiency here. My understanding is that the phase III trial took in late-onset individuals aged 12 and up — but on its own, would an approval covering that group carry real commercial weight, or is the commercial upside really contingent on ultimately reaching the severe neonatal forms, i.e., patients younger than 12? Do you have any separate pediatric study in the works, or would that hinge on what the 2027 data show? Thank you.

Emil Kakkis executive
#57

Yeah. Thanks. On the OTC program, I'd say the data looked genuinely outstanding when it comes to bringing ammonia into normal range. Also, when ammonia levels were elevated, they came down to normal in that group too—so levels normalized among patients whose condition was well managed as well as those whose control was poor. The treatment yielded robust scores on the global impression scale: 89% reached +2 or +3, meaning much better or very much better. Of those, 75% hit +3, very much better, compared with 0% on placebo. Beyond that, the control arm experienced five hyperammonemic crises along with one death, whereas the treated arm saw just a single crisis and no deaths. So looking at the overall data profile, it is in fact quite compelling. And note that this is all on top of existing therapy. From our perspective, the late-onset franchise is a valuable one, and given the favorable characteristics, the straightforward infusion, and the solid safety profile we see, I think it would hold up very well over time. On the question of whether pediatric patients ought to be included, that's something we've discussed previously, and eventually we intend to run a study in children. My reasoning is this: if a child comes in with a hyperammonemic crisis, managing that case through dialysis plus an urgent liver transplant would, I believe, be handled better by administering an IV infusion that lets the patient produce their own OTC. That approach might sustain them for a couple of years or so — say, until a transplant is completed or some other development occurs. Pediatrics and the severe form are definitely areas of interest, yet I believe the late-onset variants of the program could still yield a solid product—especially given the compelling data we have already shared.

Joshua Higa executive
#58

Thanks. Operator, let's move on to the next question, please.

Ben Burnett analyst
#59

All right, that's great, thanks. There's also something I'd like to ask regarding DTX301 OTC. Could you describe how the open-label part of the phase III is designed, and what complete responder rate is required for statistical success here?

Emil Kakkis executive
#60

Yes. As far as the trial's design goes, it was also reconfigured midway through, and there's a randomized placebo control period lasting 36 weeks, which will compare ammonia control with no change in the background therapy. What we found is that patients didn't want to remove background therapy or diet control when they didn't know whether they'd received the gene therapy. So what we do is have them cross over onto open label. They get treated, all of them are in open label, and once on open label, the doctor will then determine whether they can come off their treatments. I don't know whether Eric would like to comment on the criterion for success for the second endpoint.

Eric Crombez executive
#61

Right, so the exact way we powered that study hasn’t been disclosed, but what we’re after is complete responders—patients who can come entirely off alternate pathway medication and diet. Then responders, meaning those who can get at least 50% down from there, and we look at those combined as a responder rate.

Emil Kakkis executive
#62

Those two — go right ahead.

Ben Burnett analyst
#63

Oh, thanks. To make sure I understand: are doctors in this case told they should try to taper patients off standard of care, or is that basically left to each physician's own judgment depending on what they observe with plasma ammonia levels?

Eric Crombez executive
#64

Yes, we-.

Emil Kakkis executive
#65

Well-.

Eric Crombez executive
#66

Guidelines are in place for that, and it follows the protocol. On top of that, we stay in very close touch with the treating sites, which is one of the advantages in rare disease, where the number of patients at trial sites is relatively small. That lets us follow those patients closely and keep an active dialogue going about really pushing toward tapering and giving the gene therapy a genuine opportunity to work.

Emil Kakkis executive
#67

I put one thing forward too is-.

Ben Burnett analyst
#68

Appreciate that context.

Emil Kakkis executive
#69

Sure—the responder definition was simply something that got added in, but keeping ammonia in check is on its own a validated surrogate for rare, and that ought to be an approvable product exactly as it stands. Honestly, whether or not they're taking their other treatment doesn't really matter. What matters is whether they achieve better ammonia control, and whether they feel—does it help their function improve? In the blinded portion of the study, the data demonstrate far better ammonia control and that they feel far better, and I believe that's the key point. Our view is the drug is working, and everything else is largely an operational matter of how far they can push titration and whether they're at ease doing so—incidentally, since these patients have spent their whole lives deeply fearful of hyperammonemia, given those crises are severe and can threaten life. At present, we're quite pleased with what DTX301 has shown us. It came across very strongly in the trial, in my view.

Ben Burnett analyst
#70

That's fantastic detail. Many thanks.

Yanzhe Zhang analyst
#71

Hello, I'm Yanzhe, filling in for Ram Selvaraju. Appreciate you taking my question. It's about GENGLYCOS. Would you go into more detail regarding the post-marketing confirmatory requirements tied to accelerated approval, and which clinical evidence and timeline you've settled on with the FDA to support the switch to traditional approval? And do you know how much of that development work is reflected in your lowered 2027 R&D spending guidance?

Emil Kakkis executive
#72

Yes, so that post-marketing program is definitely included in our operating spend guidance. It falls under what we term R&D spend for commercial products. That would be one of them; we reached agreement with FDA to adopt our disease monitoring program strategy, which will enroll 50 patients receiving commercial drug — in other words, paid commercial drug — and we'll track them and their outcomes, and we'll compare against 20 patients who attempted to receive treatment but had antibodies present to AAV8, which made them ineligible for treatment, and those become the 20 control patients. So that's the fundamental design of the trial; essentially we're going to replicate what we did previously, except here it's entirely open label. The trouble was that when we were required to run a placebo-controlled trial, that created a lot of difficulty managing starch without knowing what's happening with your glucose, and we believe that did compromise the results; we believe they could be better, as we saw in the crossover. I don't know whether, Eric, you'd like to say something about the phase III in a moment, but the endpoints we discussed with FDA are actually endpoints we have already assessed. In fact, those endpoints succeeded — lowering the number of doses and the fundamental time to hypoglycemia measures. Those are areas where we've already demonstrated improvements, so we're simply going to replicate that result in an open-label format. I don't know if there's anything further, Eric, to clarify there.

Eric Crombez executive
#73

Yeah, you're right about that. What I'd say is the real emphasis is on reproducing those outcomes in the phase III trial and examining glucose control through several lenses, including a controlled fasting challenge.

Emil Kakkis executive
#74

Naturally, we could have avoided all of this if we had secured an arrangement barring placebo control from the outset — something we were obligated to pursue — and that is how we ended up where we are now. Yet since these patients are commercial, it actually reshaped our cost structure quite dramatically, and it is much cheaper, which let us run a larger study, and that matched what we had agreed with them. Still, we believe the data will prove valuable for the product over time, because we will be able to demonstrate what occurs once patients genuinely understand their starch and glucose amounts, and they know precisely what is happening while you are titrating. And we believe it will serve as a stronger data set to help support the product as it keeps expanding worldwide.

Yanzhe Zhang analyst
#75

Understood. Thanks very much.

Lachlan Hanbury-Brown analyst
#76

Yeah. Appreciate the question. I'd like to build on that topic of how urgent it is to treat with FAYUVI and ask what you're observing on that front so far. In other words, are physicians reaching out to patients and having them book a dedicated visit to come in and receive treatment, or is it perhaps the patients and their families arranging that on their own, or do they simply hold off until their next already-scheduled visit and raise it then?

Emil Kakkis executive
#77

Yeah. No, this isn't the kind of thing that waits for a next scheduled appointment; here patients are the ones calling the doctors, and the doctor then calls us saying, "We need to get something moving." These patients have been waiting for this for an eternity, and they understand that each month of delay means brain lost for their child; so it's very much patient-driven. The physicians are pulling out all the stops to assemble things and to handle the QTC issues and get everything arranged; so it's also been international. A fair number of patients from outside the U.S. too. We're working through all of it. But I think this is a disease state that, in terms of demand and desire, sits closer to SMA, which carried that same sort of urgency where every month of loss had an impact on what would happen to them. What's different is that FAYUVI will include patients who could be five, seven, eight, even 10 years old, within that range, rather than only one or two years as was the case with SMA; so there's actually a potentially broader age range of patients who will be driving this. We've already received inquiries and support starting from a wide span of ages. So, it's definitely patient-driven, and we're getting all the pieces in place to meet that demand.

Lachlan Hanbury-Brown analyst
#78

Great, thanks.

Laura Chico analyst
#79

Good evening, and thank you. I'd like to build on the strategy discussion. Emil, the remarks you made earlier about five programs per year were useful. At this stage, what would be the most effective way to refill the pipeline? I suppose my question is really about how you'll source opportunities going forward, and which parts of the orphan disease landscape would make the most sense given the commercial footprint you already have? Thank you.

Emil Kakkis executive
#80

Yeah. So, throughout our history it's always been a mix of insourcing — things we've built through our own R&D — and outsourcing through BD deals. Both types we've done. We actually have a couple of IND-ready programs, for creatine transporter deficiency and CDKL5, that are at the IND stage. But those are just a couple in hand; both are substantial opportunities when it comes to patient numbers. So those would be a couple already in hand that we've already developed and where we've already put money into the IND enabling work; so those are a couple that could come forward. But at the moment, we're trying to finish what we're doing with OTCs, setrusumab, and we also have the UX016 program for GNE myopathy, which is funded 100% by venture philanthropy. So right now, mainly, I think we have a couple of internal opportunities. On the external side, things get pitched to us constantly, but we're going to be very selective and smart about the choices, and we're going to stay within our confines of being profitable; so I wouldn't expect us to do large, costly deals, right? These will be smart, intent, intelligent choices of products with high value, particularly where our expertise can unlock value that others might not be able to. Hopefully that's helpful, Laura. Thank you for the question.

Joshua Higa executive
#81

Thanks, everyone. That brings us to the end of today's call. Should anything else come up, feel free to reach out by phone or email us at ir@ultragenyx.com. We appreciate your time with us today.

Operator operator
#82

Ladies and gentlemen, we appreciate you joining us. That brings today's teleconference to a close. Kindly hang up your lines, and enjoy the rest of your day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Ultragenyx Pharmaceutical Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Ultragenyx Pharmaceutical Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.